These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21360607)

  • 1. Looking at the proteases from a simple perspective.
    Castro HC; Abreu PA; Geraldo RB; Martins RC; dos Santos R; Loureiro NI; Cabral LM; Rodrigues CR
    J Mol Recognit; 2011; 24(2):165-81. PubMed ID: 21360607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteases universally recognize beta strands in their active sites.
    Tyndall JD; Nall T; Fairlie DP
    Chem Rev; 2005 Mar; 105(3):973-99. PubMed ID: 15755082
    [No Abstract]   [Full Text] [Related]  

  • 3. Update 1 of: Proteases universally recognize beta strands in their active sites.
    Madala PK; Tyndall JD; Nall T; Fairlie DP
    Chem Rev; 2010 Jun; 110(6):PR1-31. PubMed ID: 20377171
    [No Abstract]   [Full Text] [Related]  

  • 4. Crystal structure of chagasin, the endogenous cysteine-protease inhibitor from Trypanosoma cruzi.
    Figueiredo da Silva AA; de Carvalho Vieira L; Krieger MA; Goldenberg S; Zanchin NI; Guimarães BG
    J Struct Biol; 2007 Feb; 157(2):416-23. PubMed ID: 17011790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors.
    Overall CM; Tam EM; Kappelhoff R; Connor A; Ewart T; Morrison CJ; Puente X; López-Otín C; Seth A
    Biol Chem; 2004 Jun; 385(6):493-504. PubMed ID: 15255181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opportunities for structure-based design of protease-directed drugs.
    Mittl PR; Grütter MG
    Curr Opin Struct Biol; 2006 Dec; 16(6):769-75. PubMed ID: 17112720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding HIV protease: can it be translated into effective therapy against AIDS?
    Tang J; Lin Y; Co E; Hartsuck JA; Lin X
    Scand J Clin Lab Invest Suppl; 1992; 210():127-35. PubMed ID: 1455175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproteases in preventing the invasive potential of pancreatic cancer cells.
    Takahashi H; Sawai H; Funahashi H; Matsuo Y; Yasuda A; Ochi N; Sato M; Okada Y; Takeyama H
    JOP; 2007 Jul; 8(4 Suppl):501-8. PubMed ID: 17625307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting proteases: successes, failures and future prospects.
    Turk B
    Nat Rev Drug Discov; 2006 Sep; 5(9):785-99. PubMed ID: 16955069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of alpha-keto-based inhibitors of cruzain, a cysteine protease implicated in Chagas disease.
    Choe Y; Brinen LS; Price MS; Engel JC; Lange M; Grisostomi C; Weston SG; Pallai PV; Cheng H; Hardy LW; Hartsough DS; McMakin M; Tilton RF; Baldino CM; Craik CS
    Bioorg Med Chem; 2005 Mar; 13(6):2141-56. PubMed ID: 15727867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protease inhibitors of the sulfonamide type: anticancer, antiinflammatory, and antiviral agents.
    Supuran CT; Casini A; Scozzafava A
    Med Res Rev; 2003 Sep; 23(5):535-58. PubMed ID: 12789686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delineating protease functions during cancer development.
    Affara NI; Andreu P; Coussens LM
    Methods Mol Biol; 2009; 539():1-32. PubMed ID: 19377975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological activity and clinical implications of the matrix metalloproteinases.
    Rydlova M; Holubec L; Ludvikova M; Kalfert D; Franekova J; Povysil C; Ludvikova M
    Anticancer Res; 2008; 28(2B):1389-97. PubMed ID: 18505085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extracellular and cell surface proteases in wound healing: new players are still emerging.
    Moali C; Hulmes DJ
    Eur J Dermatol; 2009; 19(6):552-64. PubMed ID: 19625234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Proteases in Cystic Fibrosis Lung Disease. Paradigms, Progress, and Potential.
    McKelvey MC; Weldon S; McAuley DF; Mall MA; Taggart CC
    Am J Respir Crit Care Med; 2020 Jan; 201(2):141-147. PubMed ID: 31626562
    [No Abstract]   [Full Text] [Related]  

  • 16. Structural role of the 30's loop in determining the ligand specificity of the human immunodeficiency virus protease.
    Swairjo MA; Towler EM; Debouck C; Abdel-Meguid SS
    Biochemistry; 1998 Aug; 37(31):10928-36. PubMed ID: 9692985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of proteases as anticancer drugs.
    Jedinak A; Maliar T
    Neoplasma; 2005; 52(3):185-92. PubMed ID: 15875078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative studies on inhibitors of HIV protease: a target for drug design.
    Jayaraman S; Shah K
    In Silico Biol; 2008; 8(5-6):427-47. PubMed ID: 19374129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of fluorescent imaging to investigate pathological protease activity.
    Blum G
    Curr Opin Drug Discov Devel; 2008 Sep; 11(5):708-16. PubMed ID: 18729022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunolocalization and characterization of two novel proteases in Leishmania donovani: putative roles in host invasion and parasite development.
    Choudhury R; Das P; De T; Chakraborti T
    Biochimie; 2010 Oct; 92(10):1274-86. PubMed ID: 20595064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.